Axsome Wins FDA Approval for Alzheimer's Agitation Treatment

The FDA has approved Axsome Therapeutics' drug for treating agitation in Alzheimer's disease patients, providing a new therapeutic option for managing this challenging symptom. The approval marks a significant development for caregivers and clinicians who have limited treatment options for Alzheimer's-related agitation, which affects a substantial portion of patients with the neurodegenerative disease. Axsome Therapeutics now has regulatory authorization to market this treatment in the United States under FDA jurisdiction.

FDA Leadership Changes at CBER

• ▪The FDA continues to search for a permanent leader for CBER
• ▪The FDA named Katherine Szarama acting head of CBER

Julia Vitarello's New Bespoke Medicine Initiative

• ▪Julia Vitarello's first startup faltered
• ▪Julia Vitarello is launching a new effort to scale bespoke medicines

J. Craig Venter's Legacy in Genomics

• ▪J. Craig Venter's vision helped shape modern biotech
• ▪J. Craig Venter is a genomics pioneer